SCHEMBL6760907

SCHEMBL6760907

COc1ccc(NC(=O)Nc2cccc(N)c2)c(O)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 2/20 0.59
MAPT P10636 7/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
PKM P14618 2/20 0.57
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
TRPV1 Q8NER1 1/20 0.54
ALDH1A1 P00352 3/20 0.53
HTT P42858 2/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.50
MITF O75030 1/20 0.50
CDK8 P49336 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763008 0.85 CXCR2 (0.67) MAPTMEN1KMT2APKMTP53
SCHEMBL6763526 0.85 MAPT (0.77) MAPTMEN1KMT2APKMTP53
SCHEMBL6765010 0.85 MEN1 (0.60) MAPTMEN1KMT2APKMTP53
SCHEMBL6760893 0.85 ALDH1A1 (0.60) MAPTMEN1KMT2APKMTP53
SCHEMBL6763521 0.85 FADS1 (0.64) MAPTMEN1KMT2APKMTP53
SCHEMBL4356025 0.84 TRPV1 (0.70) MAPTMEN1KMT2APKMTP53
SCHEMBL6767742 0.84 MAPT (0.64) MAPTMEN1KMT2APKMTP53
SCHEMBL6764102 0.81 CXCR1 (0.62) MAPTMEN1KMT2APKMTP53
SCHEMBL1463349 0.81 GSK3A (0.66) MAPTMEN1KMT2ATRPV1ALDH1A1
SCHEMBL6763519 0.81 MEN1 (0.70) DDX3XMAPTMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063742-A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity NEUROSEARCH A/S (DK) 2004-04-01 US claimed
US-20040063742-A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity NEUROSEARCH A/S (DK) 2004-04-01 US disclosed